Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
ABL Diagnostics S.A. is a biotechnology company specializing in innovative molecular biology tests and comprehensive solutions for microbiology diagnostics. It develops and markets proprietary assays including DeepChek® for genotyping through DNA sequencing and UltraGene® for molecular polymerase chain reaction (PCR) detection, targeting infectious diseases such as HIV drug resistance, SARS-CoV-2, tuberculosis, hepatitis B and C, HPV, and microbiome analyses via 16S/18S RNA. The company also offers integrated digital solutions like Nadis®, an electronic medical record system used in French hospitals for managing HIV and hepatitis patients, and MediaChek® clinical sample collection kits. Additional products encompass real-time syndromic PCR tests, analysis software, lab automation tools, and instruments for DNA/RNA extraction, real-time PCR systems, liquid handling robots, and next-generation sequencing. ABL Diagnostics S.A. serves academic clinical pathology laboratories, private reference labs, and researchers worldwide through its sales team and exclusive distributor network across all continents, with a significant portion of sales from exports. Headquartered in Woippy, France, it markets products from its sister company CDL Pharma and operates a U.S. subsidiary for expanded reach in the medical diagnostics sector.
€2.44
€0.08 (-3.17%)
EOD Aug 14, 2026
Operating margin is thin at 4.18%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue up 30.4% YoY with margins expanding 13.3pp.
At 40x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
39.8x earnings, 55.0x FCF. Not cheap, the quality is already reflected in the price. Upside from here requires either margin expansion or growth re-acceleration, not just continuation.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€7M
▲ +30.4% YoY
Net Income (TTM)
€987K
▲ +246.0% YoY
Op. Margin
4.18%
▲ +13.3pp YoY
ROIC
2.92%
▲ +6.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€715K
▲ +130.9% YoY
Op. Cash Flow (TTM)
€902K
▲ +300.9% YoY
Net Debt
€933K
Cash & Equiv.
€1M
3Y CAGR: -7.4%
Continue Research
At a P/E of 39.8 and a price-to-free-cash-flow of 55.0, ABL Diagnostics (ABLD.XPAR) trades above a two-stage DCF intrinsic value of about €0.71 per share, so at €2.44 the stock looks overvalued (70.8% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, ABL Diagnostics scores 46/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about €0.71 per share for ABLD.XPAR, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around €0.53. At today's €2.44, that puts the stock about 70.8% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
ABL Diagnostics scores 46 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 4.2% operating margin and a 2.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. ABLD.XPAR currently trades above its estimated intrinsic value and scores 46/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.